United States Patent 12,295,989: Scope, Claims, and US Patent Landscape for Controlled-Release PTH in Hypoparathyroidism
What is US 12,295,989 and what does it cover?
US Patent 12,295,989 claims a dosing method for hypoparathyroidism using a controlled-release PTH compound administered subcutaneously with a defined dosing frequency, dose ceiling vs PTH(1-84), and defined structural attachment to specific moieties.
The independent claim is method-focused (not composition-only). The novelty is concentrated in four technical constraints that must be met together:
- Target condition and patient setting: “treating or controlling hypoparathyroidism in a human patient.”
- Dosing route and frequency: “subcutaneous injection no more frequently than once every 24 hours.”
- Dose ceiling vs PTH(1-84): controlled-release PTH dose must correspond to ≤70% (and in a dependent claim, ≤60%) of the molar equivalent of PTH(1-84) at the same dosing frequency, where that PTH(1-84) dose is the one “required to maintain” serum albumin-adjusted calcium above 8.5 mg/dL over a 24 hour period.
- Molecular identity via structural definition: the controlled-release PTH compound is defined as being a PTH moiety with amino sequence SEQ ID NO:51 attached through an amide bond to an N-terminal amine group of a PTH moiety “by an amide bond,” and further attached to a moiety where m and p are independently integers from 400 to 500 (polymeric segment length constraint).
This claim structure creates a narrow but high-value “win condition” for infringement: even if a competitor has a long-acting PTH molecule and once-daily dosing, the compound must land within the specific structural definition and meet the dosing ceiling expressed relative to PTH(1-84) for the serum calcium endpoint.
What are the claim elements and infringement-critical limitations (Claim 1)?
Claim 1 can be decomposed into the following mandatory elements:
A. Medical use
- “A method of treating or controlling hypoparathyroidism in a human patient”
B. Administered product and route
- Administer “a pharmaceutical composition comprising at least one controlled-release PTH compound or a pharmaceutically acceptable salt thereof”
- Administer “by subcutaneous injection”
C. Frequency cap
- “no more frequently than once every 24 hours”
D. Dose ceiling tied to calcium endpoint performance of PTH(1-84)
- Use “a dosage of the controlled-release PTH compound that corresponds to no more than 70% of the molar equivalent dose of PTH 1-84 administered by subcutaneous injection at the same dosing frequency required to maintain a serum albumin-adjusted calcium level in serum of above 8.5 mg/dL over a 24 hour period”
This is a conditional numeric limitation. In practice, it ties the accused dosing to:
- a reference dosing benchmark for PTH(1-84) (the amount required to keep corrected calcium above 8.5 mg/dL over 24 hours), then
- constrains the controlled-release PTH dose as a percentage of that benchmark.
E. Structural identity: controlled-release PTH compound definition
- The controlled-release PTH compound is “of formula: wherein the unmarked dashed line indicates the attachment to the N-terminal amine group of -D, which is a PTH moiety having the amino sequence of SEQ ID NO:51, by an amide bond”
- “dashed line marked with the asterisk indicates attachment to a moiety wherein each of m and p is independently an integer from 400 to 500”
Infringement-critical consequence: the claim is not just “long-acting PTH”; it is a controlled-release PTH defined by a specific PTH moiety sequence (SEQ ID NO:51) and a specific range for polymer segment parameters (m and p in 400 to 500).
How do dependent claims narrow the scope (Claims 2-5)?
Claim 2: once-daily administration
- “administered once every 24 hours.”
This tightens Claim 1’s “no more frequently than” language into a specific schedule. If an accused regimen is less frequent than daily, Claim 2 would not read; Claim 1 still could, depending on the exact frequency and other constraints.
Claim 3: delivery device
- “administered with a pen injector.”
This adds a product-administration limitation tied to the device. For infringement, the method must be practiced with the claimed delivery system (or an equivalent that courts treat as meeting the limitation). It can be used as a design-around pressure point: using a syringe delivery workflow may avoid Claim 3 without changing the drug or dosing parameters.
Claim 4: tighter dose ceiling (≤60% vs ≤70%)
- “dosage… corresponds to no more than 60% of the molar equivalent dose of PTH 1-84… required to maintain… above 8.5 mg/dL over a 24 hour period.”
This narrows the dosing window. An accused regimen with a controlled-release PTH dose above the 60% threshold can be argued not to meet Claim 4 while still possibly infringing Claim 1 if it remains at or below 70%.
Claim 5: pharmaceutical composition pH range
- “pH ranging from and including pH 3 to pH 8.”
This is a formulation constraint. It becomes relevant when a competitor uses a different buffer/pH outside that range or uses a salt/formulation variation.
What is the practical dosing and performance logic embedded in Claim 1?
The core numeric logic is a comparative potency constraint anchored to a defined pharmacodynamic endpoint:
- Endpoint: “serum albumin-adjusted calcium… above 8.5 mg/dL over a 24 hour period”
- Reference comparator: “PTH 1-84 administered by subcutaneous injection at the same dosing frequency required” to maintain that endpoint
- Controlled-release limitation: controlled-release PTH dosage is capped at a percentage of the comparator molar equivalent dose.
This makes Claim 1 a “dose-by-performance” claim even though it is phrased as a percentage. In litigation terms, the prosecution history and examples (not provided here) would usually matter most to lock down:
- how “required to maintain” was determined (clinical trial data? modeling? in a defined population?),
- what correction formula was used for “albumin-adjusted calcium,” and
- whether the “same dosing frequency” is interpreted strictly as once daily in the claim (because Claim 1 also restricts frequency to ≤ once every 24 hours).
Given Claim 1’s frequency limit, most practices will interpret “same dosing frequency” as the accused regimen’s frequency (at or below daily), and the comparator PTH(1-84) dosing frequency as that same frequency.
What does the structural limitation imply for design-around?
The structural limitation has two axes:
- PTH moiety identity: amino sequence “SEQ ID NO:51”
- Controlled-release moiety parameters: m and p are independently integers from 400 to 500
Those ranges are tight enough to provide direct design-around pathways:
- Altering the polymer segment lengths so that m or p falls outside 400–500 can avoid literal infringement of the compound structure definition.
- Altering the attachment chemistry (e.g., not via the N-terminal amine amide bond as claimed) can avoid literal infringement if the claim is construed strictly around “by an amide bond” and the specific attachment location.
- Substituting a different PTH moiety that is not “SEQ ID NO:51” avoids literal infringement.
Claim construction risk: competitors often attempt to argue non-essential differences or functional equivalence. But the claim text ties the controlled-release compound to explicit formula structure parameters, which courts often treat as literal limitations.
What is the patent landscape pressure in the US for long-acting PTH in hypoparathyroidism?
Within the US, the landscape for hypoparathyroidism long-acting PTH methods typically clusters around:
- PTH(1-84) dosing paradigms and corrected calcium endpoints
- Long-acting / depot / conjugate PTH approaches with controlled release
- Once-daily or infrequent administration schemes
- Formulation pH and stability constraints (for composition claims)
- Delivery-device-specific methods (pen injector workflows)
US 12,295,989 specifically targets the overlap of those clusters:
- It is a method-of-treatment claim with a controlled-release conjugate defined by sequence and parameter ranges, plus
- a dosing ceiling percentage relative to PTH(1-84) with the albumin-adjusted calcium endpoint, and
- dependent claim coverage for once-daily administration, pen injector use, and composition pH 3–8.
That combination usually creates strong “stacking” pressure, because a later entrant trying to claim a new long-acting PTH method typically has to change either:
- the molecular identity/structure parameters, or
- the dosing logic tied to the comparative PTH(1-84) benchmark and calcium endpoint, or
- the formulation pH and/or device workflow.
How broad is the claim relative to competitor activity? (Scope map)
The claim scope has a narrow “compound identity gate” and a broader “dose logic gate,” with additional dependent claim add-ons.
Scope gate matrix
| Scope element |
Claim 1 |
Claim 2 |
Claim 3 |
Claim 4 |
Claim 5 |
| Hypoparathyroidism treatment |
Yes |
Yes |
Yes |
Yes |
Yes |
| Human patient |
Yes |
Yes |
Yes |
Yes |
Yes |
| Subcutaneous injection |
Yes |
Yes |
Yes |
Yes |
Yes |
| Frequency |
≤ once/24h |
= once/24h |
Not specified |
≤ once/24h |
Not specified |
| Controlled-release PTH compound identity |
Yes (SEQ ID NO:51 + m,p 400-500) |
Yes |
Yes |
Yes |
Yes |
| Dose cap vs PTH(1-84) |
≤70% |
Yes |
Yes |
≤60% |
Yes |
| Albumin-adjusted calcium endpoint |
Yes (>8.5 mg/dL over 24h) |
Yes |
Yes |
Yes |
Yes |
| Pen injector device |
Not required |
Not required |
Yes |
Not required |
Not required |
| Composition pH |
Not required |
Not required |
Not required |
Not required |
3 to 8 |
What this means operationally
- A competitor using a different long-acting PTH conjugate (different segment parameters or different PTH moiety sequence) can avoid the main gate.
- A competitor using the same compound class but a higher relative dosing rate (above the 60% or 70% comparative thresholds) risks missing the method claim’s numeric requirement, even if they achieve the calcium endpoint.
- A competitor maintaining corrected calcium above 8.5 mg/dL using a regimen that requires a comparator PTH(1-84) dose benchmark might still avoid if the controlled-release dose exceeds the allowed percentage or the dosing frequency differs (for Claim 2).
- A competitor using a different delivery method (not a pen injector) can reduce exposure to Claim 3 without changing the drug.
Claim construction hotspots that affect enforcement
Even without the full specification or the formula rendering, the claim text points to common litigation interpretation issues:
-
“no more frequently than once every 24 hours”
- Impacts the method timing window.
- Does not require exactly 24 hours; allows less frequent administration under Claim 1 but not under Claim 2.
-
“controlled-release PTH compound”
- The claim requires the compound to match the formula definition, so “controlled-release” likely tracks the structural definition rather than a generic functional property.
-
“dosage… corresponds to no more than 70% of the molar equivalent dose”
- “Molar equivalent” is a calculation constraint that depends on molecular weight and active moiety definition.
- “Corresponds to” suggests comparative calculation rather than an absolute mass dose.
-
“required to maintain… above 8.5 mg/dL over a 24 hour period”
- Ties the reference PTH(1-84) dose to the corrected calcium endpoint.
- “Required” can become a proof-intensive point because it is a counterfactual benchmark: what PTH(1-84) dose would be required at the same frequency in the relevant patient population.
-
Parameter definition “each of m and p is independently an integer from 400 to 500”
- This is a precise structural range. It can be tested via product characterization methods (if available).
US patent landscape takeaways for investors and R&D planners
A competitor’s risk posture under US 12,295,989 will typically hinge on three decisions: molecular identity, dosing strategy, and administration workflow.
Decision 1: molecule selection
- If the competitor’s controlled-release PTH conjugate does not match the structural definition (SEQ ID NO:51 moiety and m,p range 400-500), exposure to the core method claim drops sharply.
Decision 2: dosing strategy anchored to the PTH(1-84) benchmark
- If the competitor’s controlled-release PTH achieves calcium control at a dose that is more than 70% (or more than 60% for Claim 4) of the molar equivalent reference dose, they can fall outside the numeric limitations even if the endpoint is met.
Decision 3: device and formulation choices
- A competitor targeting pen-only workflows increases risk under Claim 3.
- Formulation pH outside 3–8 can reduce risk under Claim 5.
Key Takeaways
- US 12,295,989 claims a method-of-treatment for hypoparathyroidism using a defined controlled-release PTH conjugate administered subcutaneously no more than once daily, with a comparative dosing ceiling tied to PTH(1-84) required to maintain albumin-adjusted calcium >8.5 mg/dL over 24 hours.
- The enforcement lever is the combination of:
- compound structure parameters (SEQ ID NO:51 PTH moiety; m and p = 400 to 500; N-terminal amide attachment),
- dose ceiling (≤70% in Claim 1; ≤60% in Claim 4),
- and route/frequency plus dependent limitations (once-daily in Claim 2, pen injector in Claim 3, pH 3–8 in Claim 5).
- Design-around most likely requires changing at least one of:
- the controlled-release compound’s structural identity (m,p range or PTH sequence),
- the dosing calculation relative to PTH(1-84) reference requirements,
- or the administration device and/or formulation pH to avoid dependent claim capture.
FAQs
1) Does Claim 1 cover both treatment and “controlling” hypoparathyroidism?
Yes. Claim 1 explicitly covers “treating or controlling hypoparathyroidism in a human patient,” both terms within the same method frame.
2) Can a regimen dosed less often than once every 24 hours still fall under Claim 1?
Yes. Claim 1 requires “no more frequently than once every 24 hours,” so less frequent dosing can still meet the frequency limit (while Claim 2 would not).
3) What is the decisive numeric threshold for Claim 4?
Claim 4 requires the controlled-release PTH dose to correspond to no more than 60% of the molar equivalent dose of PTH(1-84) required to maintain albumin-adjusted calcium above 8.5 mg/dL over 24 hours.
4) Is “pen injector” required for Claim 1?
No. Claim 3 adds “pen injector” as a dependent limitation; Claim 1 does not require the device.
5) What pH values are covered under Claim 5?
Claim 5 limits the pharmaceutical composition pH to 3 through 8 inclusive.
References
[1] US Patent 12,295,989 (claims as provided in prompt).
